

## CPT® Category I and Proprietary Laboratory Analyses (PLA) Codes for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])

**Most recent changes to this long descriptor document:**

- Addition of 2 new parenthetical notes following code 87637 and one new code (87913) and two parenthetical notes following code 87902.
- Please note the vaccine codes for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) can be found at <https://www.ama-assn.org/practice-management/cpt/covid-19-cpt-vaccine-and-immunization-codes>.
- Further updates to this document will only occur when there are additional modifications to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) codes other than vaccines
- Deleted codes in this document appear with a ~~strike through~~.

It is important to note that further CPT Editorial Panel or Executive Committee actions may affect these codes and/or descriptors. For this reason, code numbers and/or descriptor language in the CPT code set may differ at the time of publication. In addition, further Panel actions may result in gaps in code number sequencing.

**The following code was accepted at the March 2020 CPT Editorial Panel meeting for the 2021 CPT production cycle. This code is effective immediately on March 13, 2020. \*Note that code 87635 will be a child code under parent code 87471. It is represented here as the full long descriptor including the language from parent code 87471.**

Code	Long Code Descriptor	Released to AMA website	Effective	Publication
●87635	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), amplified probe technique	March 13, 2020	March 13, 2020	CPT® 2021

**The following codes, guidelines, and parenthetical notes were accepted and/or revised at the April 2020 CPT Editorial Panel meeting for the 2021 CPT production cycle. The codes, guidelines, and parenthetical notes are effective immediately on April 10, 2020.**

▲86318	Immunoassay for infectious agent antibody <del>(ies)</del> , qualitative or semiquantitative, single <del>s</del> step method (eg, reagent strip) <del>s</del>	April 10, 2020	April 10, 2020	CPT® 2021
#●86328	<p style="text-align: center;">severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])</p> <p>▶(For severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease {COVID-19}] antibody testing using multiple-step method, use 86769)◀</p>	April 10, 2020	April 10, 2020	CPT® 2021

## CPT® Category I and Proprietary Laboratory Analyses (PLA) Codes for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])

	<p>►The following codes (86602-86804) are qualitative or semiquantitative immunoassays performed by multiple-step methods for the detection of antibodies to infectious agents. For immunoassays by single-step method (eg, reagent strips), <del>use see</del> codes 86318, 86328. Procedures for the identification of antibodies should be coded as precisely as possible. For example, an antibody to a virus could be coded with increasing specificity for virus, family, genus, species, or type. In some cases, further precision may be added to codes by specifying the class of immunoglobulin being detected. When multiple tests are done to detect antibodies to organisms classified more precisely than the specificity allowed by available codes, it is appropriate to code each as a separate service. For example, a test for antibody to an enterovirus is coded as 86658. Coxsackie viruses are enteroviruses, but there are no codes for the individual species of enterovirus. If assays are performed for antibodies to coxsackie A and B species, each assay should be separately coded. Similarly, if multiple assays are performed for antibodies of different immunoglobulin classes, each assay should be coded separately. When a coding option exists for reporting IgM specific antibodies (eg, 86632), the corresponding nonspecific code (eg, 86631) may be reported for performance of either an antibody analysis not specific for a particular immunoglobulin class or for an IgG analysis. ◀</p> <p style="padding-left: 40px;">(For the detection of antibodies other than those to infectious agents, see specific antibody [eg, 86021-86023, 86376, 86800, 86850-86870] or specific method [eg, 83516, 86255, 86256]).</p> <p style="padding-left: 40px;">(For infectious agent/antigen detection, see 87260-87899)</p>	<p><b>Revised Guidelines Added to AMA Website</b> April 10, 2020</p>	<p><b>Revised Guidelines Effective</b> April 10, 2020</p>	<p><b>Revised Guidelines Publication</b> CPT® 2021</p>
86602	Antibody; actinomyces			
86635	<p style="text-align: center;">Coccidioides</p> <p>►(For severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease {COVID-19}] antibody testing, see 86328, 86769) ◀</p>	<p><b>Parenthetical Note Added to AMA Website</b> April 10, 2020</p>	<p><b>Parenthetical Note Effective</b> April 10, 2020</p>	<p><b>Parenthetical Note Publication</b> CPT® 2021</p>
●86769	<p>Antibody; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])</p> <p>►(For severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease {COVID-19}] antibody testing using single-step method, use 86328) ◀</p>	<p>April 10, 2020</p>	<p>April 10, 2020</p>	<p>CPT® 2021</p>
<p><b>The following code was accepted by the Executive Committee of the CPT Editorial Panel. This code is effective immediately on June 25, 2020. *Note that code 87426 will be a child code under parent code 87301. It is represented here as the full long descriptor including the language from parent code 87301. *This code was revised at the October 2020 CPT Editorial Panel meeting. Please see the October 6, 2020 listing below.</b></p>				

## CPT<sup>®</sup> Category I and Proprietary Laboratory Analyses (PLA) Codes for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])

●87426	Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19])	June 25, 2020	June 25, 2020	CPT <sup>®</sup> 2022
<b>The following codes were accepted by the CPT Editorial Panel. These codes are effective immediately on August 10, 2020.</b>				
#●86408	Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]); screen	August 10, 2020	August 10, 2020	CPT <sup>®</sup> 2022
#●86409	titer	August 10, 2020	August 10, 2020	CPT <sup>®</sup> 2022
<b>The following guidelines, parenthetical note, and codes were accepted by the CPT Editorial Panel. These guidelines, parenthetical note, and codes are effective immediately on September 8, 2020. *Note that resequenced code 86413 will follow code 86409.</b>				
#●86413	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) antibody, quantitative	September 8, 2020	September 8, 2020	CPT <sup>®</sup> 2022
99070	Supplies and materials (except spectacles), provided by the physician or other qualified health care professional over and above those usually included with the office visit or other services rendered (list drugs, trays, supplies, or materials provided)  (For supply of spectacles, use the appropriate supply codes)  ▶(For additional supplies, materials, and clinical staff time required during a Public Health Emergency, as defined by law, due to respiratory-transmitted infectious disease, use 99072)◀	<b>Parenthetical Note Added to AMA Website</b>  September 8, 2020	<b>Parenthetical Note Effective</b>  September 8, 2020	<b>Parenthetical Note Publication</b> CPT <sup>®</sup> 2022

## CPT® Category I and Proprietary Laboratory Analyses (PLA) Codes for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])

●99072	<p>▶Code 99072 is used to report the additional supplies, materials, and clinical staff time over and above the practice expense(s) included in an office visit or other non-facility service(s) when the office visit or other non-facility service(s) are rendered during a Public Health Emergency (PHE), as defined by law, due to respiratory-transmitted infectious disease. These required additional supplies, materials, and clinical staff time are intended to mitigate the transmission of the respiratory disease for which the PHE was declared. These include, but are not limited to, additional supplies, such as face masks and cleaning supplies, as well as clinical staff time for activities such as pre-visit instructions and office arrival symptom checks that support the safe provision of evaluation, treatment, or procedural service(s) during the respiratory infection-focused PHE. When reporting 99072, report only once per in-person patient encounter per day regardless of the number of services rendered at that encounter. Code 99072 may be reported during a PHE when the additional clinical staff duties as described are performed by the physician or other qualified health care professional in lieu of clinical staff. ◀</p> <p>Additional supplies, materials, and clinical staff time over and above those usually included in an office visit or other non-facility service(s), when performed during a Public Health Emergency, as defined by law, due to respiratory-transmitted infectious disease</p>	<p><b>Guidelines and Code Added to AMA Website</b></p> <p>September 8, 2020</p>	<p><b>Guidelines and Code Effective</b></p> <p>September 8, 2020</p>	<p><b>Guidelines and Code Publication</b></p> <p>CPT® 2022</p>
<p><b>The following guidelines, parenthetical notes, and codes were accepted, revised, and deleted by the CPT Editorial Panel. These guidelines, parenthetical notes, and codes are effective immediately on October 6, 2020. *Please note the following: 1) Code 87426 was added at the June 25, 2020 CPT Editorial Panel meeting and further revised at the October 6, 2020 CPT Editorial Panel meeting; 2) codes 87449 and 87551 are now child codes under code 87301; and 3) code 87636 will follow code 87635.</b></p>				
86317	<p>Immunoassay for infectious agent antibody, quantitative, not otherwise specified</p> <p>▶(For immunoassay techniques for <u>non-infectious agent</u> antigens, see 83516, 83518, 83519, 83520, <del>87301-87450, 87840-87899</del>) ◀</p> <p>▶(For infectious agent antigen detection by immunoassay technique, see 87301-87451. For infectious agent antigen detection by immunoassay technique with direct optical [ie, visual] observation, see 87802-87899) ◀</p> <p>(For particle agglutination procedures, use 86403)</p>	<p><b>New and Revised Parenthetical Notes Added to AMA Website</b></p> <p>October 6, 2020</p>	<p><b>New and Revised Parenthetical Notes Effective</b></p> <p>October 6, 2020</p>	<p><b>New and Revised Parenthetical Notes Publication</b></p> <p>CPT® 2022</p>

## CPT® Category I and Proprietary Laboratory Analyses (PLA) Codes for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])

87250	Virus isolation; inoculation of embryonated eggs, or small animal, includes observation and dissection			
87255	<p>including identification by non-immunologic method, other than by cytopathic effect (eg, virus specific enzymatic activity)</p> <p>►These codes are intended for primary source only. For similar studies on culture material, refer to codes 87140-87158. Infectious agents by antigen detection, immunofluorescence microscopy, or nucleic acid probe techniques should be reported as precisely as possible. The molecular pathology procedures codes (81161, 81200-81408) are not to be used in combination with or instead of the procedures represented by 87471-87801. The most specific code possible should be reported. If there is no specific agent code, the general methodology code (eg, 87299, 87449, <del>87450</del>, 87797, 87798, 87799, 87899) should be used. For identification of antibodies to many of the listed infectious agents, see 86602-86804. When separate results are reported for different species or strain of organisms, each result should be coded separately. Use modifier 59 when separate results are reported for different species or strains that are described by the same code. ◀</p> <p>►When identifying infectious agents on primary source specimens (eg, tissue, smear) microscopically by direct/indirect immunofluorescent assay [IFA] techniques, see 87260-87300. When identifying infectious agents on primary source specimens or derivatives via non-microscopic immunochemical techniques with fluorescence detection (ie, fluorescence immunoassay [FIA]), see 87301-87451, 87802-87899. When identifying infectious agents on primary source specimens using antigen detection by immunoassay with direct optical (ie, visual) observation, see 87802-87899. ◀</p>	<p><b>New and Revised Guidelines Added to AMA Website</b></p> <p>October 6, 2020</p>	<p><b>New and Revised Guidelines Effective</b></p> <p>October 6, 2020</p>	<p><b>New and Revised Guidelines Publication</b></p> <p>CPT® 2022</p>
▲87301	Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], <del>fluorescence immunoassay [FIA]</del> , immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, <del>multiple-step method</del> ; adenovirus enteric types 40/41	October 6, 2020	October 6, 2020	CPT® 2022
▲87305	Aspergillus	October 6, 2020	October 6, 2020	CPT® 2022
▲87320	Chlamydia trachomatis	October 6, 2020	October 6, 2020	CPT® 2022
▲87324	Clostridium difficile toxin(s)	October 6, 2020	October 6, 2020	CPT® 2022
▲87327	Cryptococcus neoformans (For Cryptococcus latex agglutination, use 86403)	October 6, 2020	October 6, 2020	CPT® 2022
▲87328	cryptosporidium	October 6, 2020	October 6, 2020	CPT® 2022
▲87329	giardia	October 6, 2020	October 6, 2020	CPT® 2022

## CPT<sup>®</sup> Category I and Proprietary Laboratory Analyses (PLA) Codes for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])

▲87332	cytomegalovirus	October 6, 2020	October 6, 2020	CPT <sup>®</sup> 2022
▲87335	Escherichia coli 0157 (For giardia antigen, use 87329)	October 6, 2020	October 6, 2020	CPT <sup>®</sup> 2022
▲87336	Entamoeba histolytica dispar group	October 6, 2020	October 6, 2020	CPT <sup>®</sup> 2022
▲87337	Entamoeba histolytica group	October 6, 2020	October 6, 2020	CPT <sup>®</sup> 2022
▲87338	Helicobacter pylori, stool	October 6, 2020	October 6, 2020	CPT <sup>®</sup> 2022
▲87339	Helicobacter pylori (For H. pylori, stool, use 87338. For H. pylori, breath and blood by mass spectrometry, see 83013, 83014. For H. pylori, liquid scintillation counter, see 78267, 78268)	October 6, 2020	October 6, 2020	CPT <sup>®</sup> 2022
▲87340	hepatitis B surface antigen (HBsAg)	October 6, 2020	October 6, 2020	CPT <sup>®</sup> 2022
▲87341	hepatitis B surface antigen (HBsAg) neutralization	October 6, 2020	October 6, 2020	CPT <sup>®</sup> 2022
▲87350	hepatitis Be antigen (HBeAg)	October 6, 2020	October 6, 2020	CPT <sup>®</sup> 2022
▲87380	hepatitis, delta agent	October 6, 2020	October 6, 2020	CPT <sup>®</sup> 2022
▲87385	Histoplasma capsulatum	October 6, 2020	October 6, 2020	CPT <sup>®</sup> 2022
▲87389	HIV-1 antigen(s), with HIV-1 and HIV-2 antibodies, single result	October 6, 2020	October 6, 2020	CPT <sup>®</sup> 2022
▲87390	HIV-1	October 6, 2020	October 6, 2020	CPT <sup>®</sup> 2022
▲87391	HIV-2	October 6, 2020	October 6, 2020	CPT <sup>®</sup> 2022
▲87400	Influenza, A or B, each	October 6, 2020	October 6, 2020	CPT <sup>®</sup> 2022

## CPT® Category I and Proprietary Laboratory Analyses (PLA) Codes for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])

▲87420	respiratory syncytial virus	October 6, 2020	October 6, 2020	CPT® 2022
▲87425	rotavirus	October 6, 2020	October 6, 2020	CPT® 2022
◆▲87426	severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19])	<b>Revised Code Added to AMA Website</b> October 6, 2020	<b>Revised Code Effective</b> October 6, 2020	<b>Revised Code Publication</b> CPT® 2022
▲87427	Shiga-like toxin	October 6, 2020	October 6, 2020	CPT® 2022
▲87430	Streptococcus, group A	October 6, 2020	October 6, 2020	CPT® 2022
▲87449	<del>Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative, multiple-step method, not otherwise specified, each organism</del>	October 6, 2020	October 6, 2020	CPT® 2022
87450	<del>single-step method, not otherwise specified, each organism</del> ▶(87450 has been deleted. For infectious agent antigen detection by immunoassay technique, see 87301-87451. For infectious agent antigen detection by immunoassay technique with direct optical [ie, visual] observation, see 87802-87899)◀	October 6, 2020	October 6, 2020	CPT® 2022
▲87451	<del>multiple-step method, polyvalent for multiple organisms, each polyvalent antiserum</del>	October 6, 2020	October 6, 2020	CPT® 2022
87471	Infectious agent detection by nucleic acid (DNA or RNA); Bartonella henselae and Bartonella quintana, amplified probe technique			
●87636	severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique	October 6, 2020	October 6, 2020	CPT® 2022

## CPT® Category I and Proprietary Laboratory Analyses (PLA) Codes for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])

●87637	<p>severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique</p> <p>►(For nucleic acid detection of multiple respiratory infectious agents, not including severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease {COVID-19}], see 87631, 87632, 87633)◄</p> <p>►(For nucleic acid detection of multiple respiratory infectious agents, including severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease {COVID-19}] in conjunction with additional target[s] beyond influenza virus types A and B and respiratory syncytial virus, see 87631, 87632, 87633)◄</p>	October 6, 2020	October 6, 2020	CPT® 2022
▲87802	Infectious agent antigen detection by immunoassay with direct optical ( <u>ie, visual</u> ) observation; Streptococcus, group B	October 6, 2020	October 6, 2020	CPT® 2022
▲87803	Clostridium difficile toxin A	October 6, 2020	October 6, 2020	CPT® 2022
#▲87806	HIV-1 antigen(s), with HIV-1 and HIV-2 antibodies	October 6, 2020	October 6, 2020	CPT® 2022
▲87804	Influenza	October 6, 2020	October 6, 2020	CPT® 2022
▲87807	respiratory syncytial virus	October 6, 2020	October 6, 2020	CPT® 2022
#●87811	severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])	October 6, 2020	October 6, 2020	CPT® 2022
▲87808	Trichomonas vaginalis	October 6, 2020	October 6, 2020	CPT® 2022
▲87809	adenovirus	October 6, 2020	October 6, 2020	CPT® 2022
▲87810	Chlamydia trachomatis	October 6, 2020	October 6, 2020	CPT® 2022
▲87850	Neisseria gonorrhoeae	October 6, 2020	October 6, 2020	CPT® 2022
▲87880	Streptococcus, group A	October 6, 2020	October 6, 2020	CPT® 2022



## CPT® Category I and Proprietary Laboratory Analyses (PLA) Codes for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])

▲87899	not otherwise specified	October 6, 2020	October 6, 2020	CPT® 2022	
<p><b>The following code was accepted by the CPT Editorial Panel. *Note that code 87428 will be a child code under parent code 87301. It is represented here as the full long descriptor including the language from parent code 87301. Additionally, this code will be resequenced to follow code 87426. Code 87428 is effective immediately on November 10, 2020.</b></p>					
#●87428	Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19]) and influenza virus types A and B	November 10, 2020	November 10, 2020	CPT® 2022	
<p><b>The following code and parenthetical notes were accepted by the CPT Editorial Panel. *Note that code 87913 will be a child code under parent code 87910. It is represented here as the full long descriptor including the language from parent code 87910. Additionally, this code will be resequenced to follow code 87902. Code 87913 is effective February 21, 2022.</b></p>					
87637	<p>Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique</p> <p>(For nucleic acid detection of multiple respiratory infectious agents, not including severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease {COVID-19}], see 87631, 87632, 87633)</p> <p>(For nucleic acid detection of multiple respiratory infectious agents, including severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease {COVID-19}] in conjunction with additional target[s] beyond influenza virus types A and B and respiratory syncytial virus, see 87631, 87632, 87633)</p> <p>▶(For infectious agent genotype analysis by nucleic acid [DNA or RNA] for severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease {COVID-19}], mutation identification in targeted region[s], use 87913)◀</p> <p>▶(For SARS-CoV-2 variant analysis, use 87913)◀</p>	<p><b>Parenthetical Notes Released to AMA Website</b></p> <p>February 21, 2022</p>	<p><b>Parenthetical Notes Effective</b></p> <p>February 21, 2022</p>	CPT® 2023	
#●87913	<p>Infectious agent genotype analysis by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), mutation identification in targeted region(s)</p> <p>▶(For infectious agent detection by nucleic acid [DNA or RNA] for severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease {COVID-19}], see 87635, 87636, 87637)◀</p> <p>▶(For SARS-CoV-2 variant analysis, use 87913)◀</p>	February 21, 2022	February 21, 2022	CPT® 2023	
<p><b>The following code was accepted by the Executive Committee of the CPT Editorial Panel for the 2021 CPT production cycle. This code is effective immediately on May 20, 2020. *The duplicate PLA symbol and parenthetical note following the code descriptor for code 0202U will be published for the first time in CPT 2022.</b></p>					
<b>Proprietary Name and Clinical Laboratory or Manufacturer</b>	<b>Code</b>	<b>Long Code Descriptor</b>	<b>Released to AMA Website</b>	<b>Effective Date</b>	<b>Publication</b>

## CPT® Category I and Proprietary Laboratory Analyses (PLA) Codes for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])

BioFire® Respiratory Panel 2.1 (RP2.1), BioFire® Diagnostics, BioFire® Diagnostics, LLC	✕●0202U	<p>Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected</p> <p>▶(For additional PLA code with identical clinical descriptor, see 0223U. See Appendix O or the most current listing on the AMA CPT website to determine appropriate code assignment)◀</p>	May 20, 2020	May 20, 2020	<p>CPT® 2021</p> <div style="background-color: #cccccc; padding: 5px; text-align: center;"> <p><b>Duplicate PLA Symbol and Parenthetical Note Added to Publication</b></p> <p>CPT® 2022</p> </div>
<b>The following codes were accepted by the Executive Committee of the CPT Editorial Panel. These codes are effective immediately on June 25, 2020.</b>					
QIAstat-Dx Respiratory SARS CoV-2 Panel, QIAGEN Sciences, QIAGEN GmbH	✕●0223U	<p>Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected</p> <p>▶(For additional PLA code with identical clinical descriptor, see 0202U. See Appendix O or the most current listing on the AMA CPT website to determine appropriate code assignment)◀</p>	June 25, 2020	June 25, 2020	CPT® 2022
COVID-19 Antibody Test, Mt Sinai, Mount Sinai Laboratory	●0224U	<p>Antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), includes titer(s), when performed</p> <p>▶(Do not report 0224U in conjunction with 86769)◀</p>	June 25, 2020	June 25, 2020	CPT® 2022
<b>The following codes were accepted by the CPT Editorial Panel. These codes are effective immediately on August 10, 2020.</b>					
ePlex® Respiratory Pathogen Panel 2, GenMark Dx, GenMark Diagnostics, Inc	●0225U	<p>Infectious disease (bacterial or viral respiratory tract infection) pathogen-specific DNA and RNA, 21 targets, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected</p>	August 10, 2020	August 10, 2020	CPT® 2022
Tru-Immune™, Ethos Laboratories, GenScript® USA Inc	●0226U	<p>Surrogate viral neutralization test (sVNT), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), ELISA, plasma, serum</p>	August 10, 2020	August 10, 2020	CPT® 2022
<b>The following codes were accepted by the CPT Editorial Panel. These codes are effective immediately on October 6, 2020.</b>					
Xpert® Xpress SARS-CoV-2/Flu/RSV (SARS-CoV-2 & Flu targets only), Cepheid	●0240U	<p>Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 3 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B), upper respiratory specimen, each pathogen reported as detected or not detected</p>	October 6, 2020	October 6, 2020	CPT® 2022
Xpert® Xpress SARS-CoV-2/Flu/RSV (all targets), Cepheid	●0241U	<p>Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 4 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B, respiratory syncytial virus [RSV]), upper respiratory specimen, each pathogen reported as detected or not detected</p>	October 6, 2020	October 6, 2020	CPT® 2022